Skip to main content

Table 1 Characteristics of included studies

From: Antibiotic prophylaxis in primary and revision shoulder replacement: a systematic review

AuthorYearStudy design (Oxford Center of EBM level)PopulationPatients with ATB therapyShoulder
Involved
Age (mean)Gender (m/f)MicroorganismType of infection (a/c) *Time of follow upAntibiotic
Pérez-Prieto[19]2016Prospective randomized and controlled study
(I)
282837415/13 A = 14;
C = 14
 Cefalosporin
Glycopeptide
Kong Koh,[20]2016Randomized study
(I)
303030747/23P. acnes 9- monthsCefazolin
Gentamicin
Lutz[21]2005Retrospective study
II
52351551,837/15P. acnes average follow-up 37.1 monthsClindamycin–Ofloxacin (n = 14PZ)
Rifampicin–Ofloxacin(n = 6PZ)
Clindamycin–Rifampicin (n = 3PZ) Cloxacillin–Ofloxacin(n = 2)
Rrifampicin–Pristinamycin (n = 2PZ)
Ceftriaxone–pristinamycin(n = 1PZ) Cefepime–Ofloxacin (n = 1PZ)
eicoplanin–Rifampicin (n = 1PZ)
Clindamycin–Fusidic Acid (n = 1PZ)
Clindamycin monotherapy(n = 1PZ) Vancomycin–Ceftazidime–Ciprofloxacin(n = 1PZ)
Opric a[22]2004Retrospective study
(II)
328304304  P. acnes  Clindamycin
Erythromycin
Tetracycline
Linezolyd
Benzypenicillin
Vancomycin
Matse n[23]2015Prospective study
(I)
101010range 11–5810/0P. acnes  Ceftriaxone
Vancomycin
Parad a[24]2018An on-line survey
(V)
846262  P. acnes  Cefazolin
Vancomicin
Clindamycin
Al-Mayahi[25]2015Case-control study
(III)
27401167274057 S. aureus  Quinolone
Beta-Lactam
Long-Acting Agent (Vancomycin, Teicoplanin, Ceftriaxone, Ertapenem)